Introduction
============

Giant cell tumor of bone (GCTB), also known as osteoclastoma [@B1], accounts for approximately 5% of all primary bone tumors. GCTB is an expansible osteolytic tumor that most often arises at the end of a long bone in a skeletally mature patient [@B2]. This neoplasm usually affects young adults - approximately two-thirds of the patients are between 20 and 40 years of age [@B3]. GCTB most commonly involves the distal femur, proximal tibia, distal radius, proximal humerus and the sacral bone, with a slight predominance in females [@B4], [@B5].

Histologically, GCTB comprises 3 distinct cell types: multinucleated osteoclast-like giant cells, monocytic round-shaped macrophage-like cells, spindle-shaped and fibroblast-like stromal cells. The stromal cells of GCTB are the primary neoplastic cells; they are the only proliferating cell component in long-term culture [@B6]. Although their exact origin has yet to be determined, the stromal cells may descend from either an osteoblastic lineage or bone marrow mesenchymal cells, which might both regulate the formation of multinucleated osteoclast-like giant cells in the neoplasm [@B7]. The stromal cells of GCTB may drive the macrophage-like cells to undergo fusion to form multinucleated osteoclast-like giant cells, and the latter eventually cause aggressive bone resorption and skeletal destruction [@B8].

The World Health Organization has classified GCTB as an aggressive, potentially malignant lesion [@B4]. Clinically, GCTB is considered benign, but it often becomes an aggressive lesion with a tendency for local recurrence. Depending on the type of treatment and the local presentation of the tumor, recurrence rates range from 0 to 65% [@B9]. GCTB is one of the rare benign tumors that can grow [@B10] intravascularly and give rise to distant metastases; slow growth and lung metastasis occur in 2 - 10% of cases [@B11]-[@B13].

The Epithelial Mesenchymal Transition (EMT) is a phenomenon which cancer cell acquires plasticity that confers features such as metastasis and recurrences. The EMT process is regulated by a number of genes distributed in compartments of cancer cell [@B14], [@B15]. To elucidate the molecular mechanisms involved in the tumorigenesis of GCTB, selected genes have been identified by analyzing gene expression [@B16]-[@B18]. Few studies, however, have investigated the genetic profile of GCTB, we have searched for to identify differentially expressed genes involved in tumorigenesis. Elucidation of these genes and the molecular mechanisms that may regulate their expression remain to be identified to achieve a better understanding of the biology of GCTB [@B19], [@B20].

The *MAP2K3* gene is related to cell proliferation. In several types of advanced cancers that lead to cell proliferation, this gene has been shown to promote cancer cell invasion and metastasis [@B21]. The *ADAM23*, *CDH2*, *CDKN2A* (*p16*), *CDK4*, *CXCL14*, *MMP14*, *NFκB*, *SNAI1*, *TIMP2*, *TIMP3*, *VIM* and *ZEB1* genes encode proteins involved in different stages of cell transformation, including cell motility, adjacent tissue invasion, tumor progression, dissemination through the vasculature and finally proliferation from a micro-metastasis to macroscopic secondary tumor [@B22]-[@B31].

In this study, we selected genes involved in cellular differentiation and proliferation in giant cell tumors of bone and analyzed their expression by qPCR. The genes *ADAM23* and *CDKN2A*were underexpressed in giant cell tumor of bone, and we report that the hypermethylation of the promoter regions of these genes controls their expression in GCTB. Furthermore, we showed, by immunohistochemistry, that overexpression of the *MAP2K3, MMP14, TIMP2* and *VIM*genes was significantly higher in CGTB than in non-neoplastic samples. Because of their role in the cellular mechanisms involved in the alteration of cellular homeostasis, these genes may be involved in the development of GCTB.

Material and methods
====================

GCTB Sample Collection
----------------------

The samples were collected from 42 patients with primary GCTB, including 23 fresh samples of GCTB, 24 paraffin-embedded samples of GCTB, 9 fresh, histologically normal bone tissue samples of femur, and 3 paraffin-embedded samples of histologically normal medullar bone tissues of femur, all of which were confirmed by pathologists. Histologically normal samples were extracted from the margin of tumors of the femur. Tissues were obtained from the Tumor Bank at The Pio XII Foundation/IBILCE-UNESP, São Paulo, Brazil. The use of all patient-derived material was approved by the institution\'s Research Ethics Board at The Pio XII Foundation of the Cancer Hospital of Barretos, and informed consent was obtained individually from the patients. The diagnosis of GCTB was established by a biopsy prior to surgical excision, and the patients had no other malignancies at the time of the surgery. The tissues were obtained during surgery from patients undergoing tumor resection, and the diagnosis of GCTB was verified post-operatively by a histopathologist. Microdissection was performed on the collected samples. The fresh samples were used to perform the quantitative real-time polymerase chain reaction, and paraffin-embedded samples were used in the methylation and immunohistochemistry analyses.

RNA Extraction
--------------

Total RNA was isolated from GCTB tissue and normal tissue using TRIzol (Life Technologies, Grand Island, NY, USA) and following the protocol instructions. For qPCR, approximately 5 μg of total RNA from each sample were used to synthesize cDNA with a High-Capacity cDNA Archive Kit (Life Technologies, Grand Island, NY, USA), according to the manufacturer\'s instructions. *β-ACTIN (ACTB)*amplification served as a control for cDNA quality.

Quantitative Real-time Polymerase Chain Reaction (qPCR)
-------------------------------------------------------

Twenty genes related to tumorigenesis, progression, cell migration and tumor malignancy were selected. We used 23 fresh CGTB samples and a pool of total RNA from a subset of 9 fresh tissue samples of normal bone, defined as the normal reference (control group). Gene-specific primers for qPCR were designed for optimal hybridization kinetics using the Primer 3.0 program (provided by the Whitehead/MIT Center for Genome Research, Cambridge, MA, USA).

Quantitative real-time PCR involved an ABI prism 7300 sequencer detector system and SYBR Green PCR Core Reagent (Life Technologies, Grand Island, NY, USA). The reaction mixture (20 μL total volume) contained 25 ng of cDNA, gene-specific forward and reverse primers for each gene, and 10 μL of 2× Quantitative SYBR Green PCR Master Mix. Relative quantification was performed using the CT values and triplicate reactions for GCTB samples and a reference sample from each gene and from the endogenous control (glyceraldehyde-3-phosphate dehydrogenase*; GAPDH)*. The primers were designed in different exons, and the sequences are available in Table [1](#T1){ref-type="table"}. Therefore, the relative expression of each specific gene was calculated by using the formula: R = (E target)^ΔCt\ target\ (control\ -\ sample)^/(E endogenous)^ΔCt\ endogenous\ (control\ -\ sample)^, as previously described [@B32]. The cut-off for the analysis of gene expression was ≥ 2 for increases and decreases in expression. A value below this cut-off was considered to indicate that the increase or decrease in expression was not significant.

DNA Extraction
--------------

DNA samples of fresh tissue were isolated using TRIzol (Life Technologies, Grand Island, NY, USA). For the extraction of DNA from paraffin, the samples were deparaffinized with xylene, and the tissue samples were digested in a buffer (100 mmol/L NaCl, 10 mmol/L Tris-HCl pH 8.0, 25 mmol/L ethylenediamine tetraacetic acid (EDTA) and 1% sodium dodecyl sulfate) containing 20 mg/mL proteinase K at 50°C for 3 days. Total DNA was isolated using phenol-chloroform extraction and ethanol precipitation. The DNA pellets were resuspended with 20 mL of TE buffer (10 mmol/L Tris-HCl, 1 mmol/L EDTA, pH 8.0) and stored at -20°C until PCR amplification. β-Globin gene (*HBB*) amplification served as a control for DNA quality.

Bisulfite Modification of DNA and Methylation-Specific PCR
----------------------------------------------------------

The genomic DNA extracted from tissues was modified using bisulfite treatment according to Calmon et al. [@B33]. The DNA methylation status in the CpG island promoter was determined using the previously described MSP procedure, which used primers specific for the methylated (M) or unmethylated (U) sequences of the bisulfite-modified DNA. The primers used for each gene in the PCR reaction were specific to methylated and unmethylated DNA (Table [2](#T2){ref-type="table"}). Bisulfite-modified DNA from peripheral blood lymphocytes from a healthy individual was previously treated and untreated with CpG methyltransferase (M.SssI) (New England Biolabs, Ipswich, MA, USA) and served as a positive control for hypermethylated and unmethylated DNA. A blank control containing all the PCR components (except template DNA) was also included in all of the experiments. Reaction products were separated using electrophoresis on an 8% polyacrylamide gel and stained with silver nitrate.

Immunohistochemistry
--------------------

Unstained 4.5 µm sections were cut from each paraffin block, deparaffinized and rehydrated using routine techniques. Endogenous peroxidase activity was blocked with 0.3% H~2~O~2~ for 30 min in a citrate buffer (10 mM, pH-6) at 95°C. Monoclonal antibodies used were anti-human MMP14 (Abcam Inc., Cambridge, MA, USA) (1:50 dilution), anti-human TIMP2 (Chemicon/Millipore, Billerica, MA, USA) (1:150 dilution), anti-human VIM (Dako, Carpinteria, CA, USA) (1:100 dilution) and polyclonal rabbit anti-human MAP2K3 (Abcam Inc., Cambridge, MA, USA) (1:50 dilution). They were applied and incubated at 4°C overnight. Afterward, sections were incubated with a biotinylated secondary antibody and exposed to a streptavidin complex (HRP Ready-to Use, DakoCytomation, Carpinteria, CA, USA). Positive reactions were visualized with 3,3\' diaminobenzidine tetrahydrochloride (DAB, Signet® Laboratories, Dedham, MA, USA), followed by counterstaining with hematoxylin.

Normal pancreas tissue was used as a positive control for TIMP2, and breast carcinoma tissue was used as the positive control for MAP2K3, MMP14 and VIM. Sections treated without primary antibodies were used as negative controls. TIMP2, MAP2K3, MMP14 and VIM densitometric analyses were conducted with an Axioskop II microscope (Zeiss, Germany) using the Software AxiovisionTM (Zeiss). For these analyses, 3 different fields from each tumor fragment were used, and 20 different points were analyzed to calculate an average intensity of immunoreactivity. The values were obtained as arbitrary units (a.u.).

Statistical Analysis
--------------------

Minitab Student 14 software was employed to perform the statistical analyses, with significance set at *p*\< 0.05. Relative expression levels detected by qPCR in CGTBs samples were transformed into natural logarithms. The Wilcoxon signed-rank test was applied to compare the gene expression levels in tumor tissue and normal bone tissue. The Kruskal-Wallis test was used to determine whether there was an association between gene expression and recurrence or metastasis. The data from protein expression were obtained using immunohistochemistry and were statistically examined with the Mann-Whitney test.

Results
=======

Patients
--------

The study population involved 42 patients. Twenty-one (50%) were male and 21 (50%) were female. Their minimum and maximum ages were 13 and 74 years, respectively, with a mean of 35.9 years ± 14.9. The most common locations of the GCTB were femur (26%), tibia (21%) and radius (14%). Eight patients (17%) experienced a recurrence between 11 and 42 months after surgery, and 6 patients (12.7%) experienced metastases between 1 and 65 months after surgery (Table [3](#T3){ref-type="table"}).

Expression of the Selected Genes
--------------------------------

The *CXCL14, CDH2, CDK4, MAP2K3, MMP14, SNAI1, TIMP2, TIMP3, VIM*and*ZEB1*genes were overexpressed in the GCTB samples compared to the reference samples (*p*\< 0.001), and the fold change of gene expression ranged from 2.03 to 6.58. *CDKN2A (p16)* and*ADAM23*were significantly downregulated in tumor tissues compared to normal bone tissue (*p*\< 0.001), and the fold change of gene expressions was found to be -6.46 and -4.70, respectively. The *NFκB* gene was not differentially expressed (Figure [1](#F1){ref-type="fig"}).

Methylation Analysis of the *ADAM23*and *CDKN2A (p16)* genes
------------------------------------------------------------

After gene expression analysis, the methylation pattern in the promoter region of the *ADAM23*and*CDKN2A (p16)* genes was analyzed using MSP-PCR in 26 GCTB samples.

Hypermethylation in the promoter regions of the *ADAM23*and *CDKN2A (p16)*genes was detected in 92% (24/26) and in 83.3% (20/24) of the tumors analyzed, respectively (Figure [2](#F2){ref-type="fig"} and Table [4](#T4){ref-type="table"}). The hypermethylation of *ADAM23* and *CDKN2A (p16)* was statistically associated with the presence of GCTB (*p* \< 0.001 and *p* \< 0.05, respectively). In addition, the sets of primers for the genes used in this study gave no indication of hypermethylation in the normal lymphocytes analyzed. The hypermethylation of the *ADAM23* gene was detected in 90.5% of the non-recurrent tumors samples and in 90.5% of the non-metastatic tumor samples. The promoter region of the *ADAM23* gene was hypermethylated in all the samples that exhibited metastasis or recurrence. Because of the small number of samples, however, no significant association could be found between the presence of hypermethylation in the promoter regions of *ADAM23*and *CDKN2A (p16)* genes and the clinicopathologic parameters of these genes in GCTB.

Immunohistochemistry of the Overexpressed Genes (*MAP2K3, MMP14, TIMP2* and *VIM*)
----------------------------------------------------------------------------------

Immunohistochemistry was performed on 24 samples of GCTB and on the normal tissue margins of the tumors. Immunohistochemical staining of GCTB samples confirmed the presence of MMP14, MAP2K3, TIMP2 and VIM in the GCTB microenvironment. Staining of the samples for MMP14, MAP2K3, TIMP2 and VIM was positive in the cytoplasm of multinucleated giant cells, stromal cells and monocytic cells (Figure [3](#F3){ref-type="fig"}A-D). In normal bone tissue there was very weak staining in different cell types of these 4 gene products (Figure [3](#F3){ref-type="fig"} E-H) and breast carcinoma and normal pancreas showed immunostaining, as representative positive controls for the selected gene products (Figure [3](#F3){ref-type="fig"}I-L). GCTB samples were found to have an increased expression of MMP14, MAP2K3, TIMP2 and VIM compared to the normal tissue margins of the tumor (*p* \< 0.05) (Figure [3](#F3){ref-type="fig"}M).

Discussion
==========

Giant cell tumor of bone is a rare type of bone tumor that is generally benign and characterized histologically by multinucleated giant cells with a background of mononuclear stromal cells [@B34]. GCTB is a tumor that, while benign, often becomes aggressive and exhibits local recurrence and small rates of metastasis [@B5], [@B35]. This type of tumor belongs to a group of benign tumors of bone, including osteoblastoma, chondroblastoma and chondromyxoid fibroma that share characteristics that are both benign and aggressive [@B36], [@B37]. GCTB has unique histological characteristics consisting of mononuclear cells and multinucleated giant cells with a variable and unpredictable growth potential [@B10]. Thus, it has several characteristics of aggressive, including a high mitotic rate, necrosis and recurrence after resection [@B38]. However, the identification of aggressive GCTB is often difficult because these tumors are rare and diagnostic criteria remain poorly defined [@B39]. The molecular mechanisms responsible for the post-surgical recurrence and rarely metastasis of GCTB are not well understood. To better understand this rare type of tumor and to avoid recurrences, it is important to elucidate the molecular biology of the tumor and the genes involved in tumorigenesis of giant cell tumor of bone.

Tumor cells are characterized by changes in gene expression and transcriptional inactivation caused by epigenetic events that can initiate the expansion of altered cells during the early stages of tumorigenesis [@B40]. Methylation is a major epigenetic modification process in human cells; changes in methylation patterns play an important role in the genesis of tumors via transcriptional inactivation. The methylation of the C-5 methyl group in DNA\'s 5\'-cytosine results in the formation of 5-methylcytosine. Methyl groups decrease the binding affinity between the promoter regions of DNA and transcription factors, which silences genes that play important roles in maintaining cellular homeostasis [@B41]. Methylation events play an important role in tumor progression and are frequent in transformed cells. The methylation of CpG islands is found in gene promoter regions, which may be associated with the repair of damaged DNA, metastases and invasiveness of the cancer genesis process [@B42]. The process of hypermethylation in the promoter region was reported in giant cell tumor of bone, for example, in the genes *UCHL1*, *IGFBP4* and *RUNX3*, which are involved in the regulation of cell proliferation, apoptosis and cell transformation [@B43] [@B44]. Therefore, we investigated if hypermethylation in the promoter region regulates the expression of the genes *ADAM23* and *CDKN2A (p16)* in giant cell tumor of bone.

The hypermethylation of the promoters of the ADAM23 and CDKN2A (p16) genes is a mechanism of silencing these genes, similar to hypermethylation in other tumor types [@B22], [@B45]. This is the first time that hypermethylation in the promoter region of the *ADAM23* and *CDKN2A (p16)*genes has been described in this type of tumor.

The *ADAM23* gene is located on chromosome 2q33 and encodes ADAM domain 23; this constitutes an Adam family of type I transmembrane glycoproteins that has a common structural organization, including a metalloprotease and disintegrin domain. This protein possesses a potent adhesion domain and is involved in cell-cell and cell-matrix interactions [@B33], which allow for contact between cells. This contact can prevent growth through contact inhibition, particularly in normal cells.

An analysis of the ADAM23 gene promoter suggests that methylation is an active epigenetic event in the silencing of gene activity. Hypermethylation of the promoter region of the ADAM23 gene has been associated with advanced breast, brain, gastric, and head and neck cancers [@B33], [@B46]-[@B48]. Furthermore, one study shows that the promoter region of this gene tends to be more frequently methylated in metastatic gastric carcinomas [@B49]. Hypermethylation of the *ADAM23* gene in primary breast tumors is significantly associated with an incidence of metastases. The loss of *ADAM23* expression may promote α~v~β~3~ integrin activation leading to enhance tumor cell migration [@B50], [@B51]. In our study, we observed that the most GCTB samples exhibited hypermethylation in the promoter region of the *ADAM23*gene. Thus, we suggest that the silencing of *ADAM23* could lead to GCTB progression because of the loss of contact inhibition and abnormal cell-matrix interactions that lead to uncontrolled cell proliferation.

The *CDKN*2A gene, also known as *p16^INK4^*, is considered a tumor suppressor gene because it is frequently observed in human cancers to be silenced through deletion or via an inactivating mutation [@B52]-[@B56]. Typically, p16 induces cell cycle arrest and prevents cell division by inhibiting the cyclin-dependent kinases CDK4 and CDK6, as well as CDK-mediated phosphorylation of the retinoblastoma gene [@B57]. The CDKN2A protein plays an important role in suppressing cell cycle progress, and downregulation of p16 could increase cell proliferation and contribute to the development of a variety of cancers [@B58], [@B59]. Moreover, CDKN2A downregulation has been confirmed using immunohistochemistry analysis in chondrosarcoma cell lines [@B60] and the presence of CDKN2A gene in enchondromas leads to low proliferative activity and the inhibition of cell-cycle progression [@B61]. The CDKN2A gene protects cells from undergoing transformation and protects the genome from mutagenic events. It also induces apoptosis in cells that escape the control of the cell [@B62].

Methylation of cytosine at CpG sites in the CDKN2A gene promoter, which results in the silencing of p16 expression, occurs in many cell lines, including those of colorectal cancer and various primary carcinomas of colon, breast, bladder, ovary, lung and bone marrow [@B63]-[@B68]. Aberrant inactivation of the CDKN2A gene by methylation is a frequent early event in multiple human cancers [@B69], [@B70], which means it is a factor of interest as a biomarker of pre-malignant alterations [@B71]. In this study, CDKN2A gene expression is suppressed possibly because of the high frequency of DNA methylation in its promoter region. The loss of CDKN2A activity as a consequence of mutations or promoter hypermethylation is a common step in the genesis and progression of tumors [@B62] because the inactivation of CDKN2A allows tumor cells to pass through the G1 cell cycle checkpoint [@B72]. Thus, we suggest that the inactivation of CDKN2A in GCTB contributes to inappropriate mitotic divisions in the giant cells leading to increased cell proliferation.

Epithelial mesenchymal transition (EMT) is essential for driving plasticity during cancer progression. Furthermore, the recurrence after therapy, common in GCTB, is one cancer-related function of EMT, cancer cells to trans-differentiate to mesenchymal cancer cells with an increased expression of many genes [@B14]. Through gene expression and immunohistochemical analyses, 4 overexpressed genes in GCTB have been identified. The expression of *MMP14*,*MAP2K3*,*TIMP2*and*VIM*genes were significantly higher in GCTB than in non-neoplastic samples. Changes in these genes might be critical to the development of GCTB.

The *MMP14*gene, which belongs to the family of zinc metalloendopeptidases, is thought to be responsible for the accelerated breakdown of the extracellular matrix (ECM), an essential event in tumorigenesis. Generally, MMPs at the metastastic sites are expressed at a higher level compared to corresponding primary tumors [@B73]. MMP-9 is expressed in giant cell tumor of bone and because normal cells such as fibroblasts do not synthesize MMP-9, the production of MMP-9 may be important for the migration of cells into the blood stream, lymphatic vessels or adjacent normal tissues [@B74]. MMP-13 has been reported to accelerate bone remodeling and promotes proliferation while inhibiting apoptosis in human osteoblast-like cells, and its expression is upregulated in giant cell tumor of bone [@B75]-[@B77]. Our study observed, for the first time, the overexpression of the *MMP14* gene in multinucleated giant cells, stromal cells and monocytic cells of GCTB. MMP14 has been detected in bone lesions from metastatic prostate cancer, and MMP14 immunostaining was detected in 80% of brain metastases from lung adenocarcinomas [@B78]. The data support the hypothesis that high levels of *MMP14* might play a role in the aggressiveness of giant cell tumor of bone, which has also been suggested for breast cancer [@B79].

The *VIM* has shown an association in different types of cancer, including prostate cancer, breast cancer, gastric cancer and gallbladder cancer [@B80]-[@B83]. Studies of the ectopic overexpression of vimentin have shown the invasive behavior of epithelial carcinoma cells, which reveal the association of vimentin with tumor invasiveness and motility [@B84], [@B85]. One previous study found expression of VIM in mononuclear cells of GCTB [@B86]. Our results show that the increased expression of vimentin in multinucleated giant cells, stromal cells and monocytic cells of GCTB is significantly associated with GCTB, and therefore, the increased expression of vimentin may act as a new indicator of this tumor. Zhao et al. [@B87] demonstrated that vimentin affects prostate cancer cell motility and invasion, and vimentin could be a predictive marker of tumors that might progress to metastatic disease. The *MAP2K3* gene is translated into a mitogen-activated protein kinase 3 and is involved in the signal transduction that controls proliferation and programmed cell death [@B88]. MAP2K3 protein is involved in the Ras-MKK3-p38-signaling cascade, the components of which may confer an invasive phenotype to the cell [@B89]. Our study shows that the *MAP2K3* gene is overexpressed in GCTB compared to normal tissue. The data support the hypothesis the MAP2K3 protein is implicated in tumor invasion and growth [@B90], [@B91].

The *metallopeptidase inhibitor 2* (*TIMP2*) gene belongs to the TIMP family. Its function is to inhibit the activity of matrix metallopeptidases [@B92]. The binding of TIMP2 with MT1-MMP stimulates invasion in the most aggressive cancers, and TIMP2 expression is associated with both tumor recurrence and a poor prognosis. Our study shows that the TIMP2 gene is overexpressed in GCTB compared to normal tissue. Giannopoulos et al. [@B93] found increased TIMP2 concentration in pancreatic cancer cells and this concentration correlates with the degree of lymphatic vessel infiltration, which ultimately leads to lymphatic node metastases.

In summary, hypermethylation of the promoter region of *ADAM23* and *CDKN2A*occurs in GCTB. The silencing of these genes may contribute to tumor progression because of a possible relationship between these genes and the adhesion domains involved in cell-cell and cell-matrix interactions, which can negatively regulate cell growth. The study also shows that overexpression of the MAP2K3, MMP14, TIMP2 and VIM genes was significantly higher in GCTB than in non-neoplastic samples. The expression of these genes may be involved in any step of the development of GCTB because of their role in the cellular mechanisms involved in the alteration of cellular homeostasis. For the first time, we were able to identify altered genes in GCTB and provide insight into tumor biology. Once these genes have been characterized in GCTB, molecular genetic tools may be used to explore the biological processes involved in this disease. In addition, our approach may provide relevant information and motivation in the development of new therapies for GCTB. Further studies with larger cohorts are required to evaluate whether the identified genes are associated with any clinicopathologic parameters of GCTB. These findings contribute to a better understanding of the tumorigenesis of GCTB and may therefore help to improve diagnosis and patient outcome.
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![**mRNA expression levels media in GCTB samples.**mRNA expression of the selected genes using qPCR. The results are shown as the fold change in expression relative to normal bone of femur. (\**p*\< 0.001, Wilcoxon Signed Rank Test)](jcav06p0593g001){#F1}

![**Representative data showing the methylation status of the promoter regions of the genes *ADAM23*and*CDKN2A (p16)*.** Lanes U and M correspond to unmethylated and methylated reactions, respectively. In each case, 3F indicates GCTB patient sample, C- indicates DNA from lymphocyte, C+ indicates *in vitro* methylated DNA (IVD), H~2~O indicates negative PCR control. On the left: molecular weight marker; and below: size of methylated PCR product.](jcav06p0593g002){#F2}

![**Immunohistochemistry in GCTB and control samples.** Protein detection of (A) MAP2K3, (B) MMP14, (C) TIMP2 and (D) VIM in giant cell tumor of bone samples by immunohistochemistry. (E-H) Normal bone samples were used as negative controls and (I, J, L) breast carcinoma and (K) normal pancreas were used as positive controls. The presence of multinucleated giant cells is marked with *asterisk*. (M) Graphic of densitometry of the immunostaining of MAP2K3, MMP14, TIMP2 and VIM in the samples analyzed. Bars = 20 μm. (\**p* \< 0.05, Mann-Whitney test).](jcav06p0593g003){#F3}

###### 

Primer sequences used in quantitative real-time polymerase chain reaction

  --------------------------------------------------------------------
  Gene                 Primer Sequence (5\' - 3\')   Size of product
  -------------------- ----------------------------- -----------------
  ***ADAM23***         F:CCACTCGATTCCAAGGGTAAAGT\    64bp
                       R:ATGCAGGTGGCTTCATTACTACAC    

  ***CDH2***           F:ATATGGCCTTTCAAACACAGC\      82bp
                       R:CGTCATGGCAGTAAACTCTGG       

  ***CDKN2A (p16)***   F:ACCAGAGGCAGTAACCATGC\       99bp
                       R:AAGTTTCCCGAGGTTTCTCAG       

  ***CDK4***           F:CCCGAAGTTCTTCTGCAGTC\       119bp
                       R:CTGGTCGGCTTCAGAGTTTC        

  ***CXCL4***          F:GAAATGAAGCCAAAGTACCCG\      152bp
                       R:TACAACGCCTGGAACG            

  ***GAPDH***          F:ACCCACTCCTCCACCTTTGA\       79bp
                       R:CTGTTGCTGTAGCCAAATTCGT      

  ***MAP2K3***         F:GCCTATGGGGTGGTAGAGAAG\      102bp
                       R:TTGATGTCCAGGTCCATGAG        

  ***MMP14***          F:CACTGCCTACGAGAGGAAGG\       149bp
                       R:GAGCAGCATCAATCTTGTCG        

  ***NFκB***           F:CCAGCTGGCAGGTATTTGAC\       100bp
                       R:TCAGCCAGCTGTTTCATGTC        

  ***SNAI1***          F:CTCTTTCCTCGTCAGGAAGC\       95bp
                       R:AGGGCTGCTGGAAGGTAAAC        

  ***TIMP2***          F:GTAGTGATCAGGGCCAAAGC\       124bp
                       R:TCTCAGGCCCTTTGAACATC        

  ***TIMP3***          F:GGGGAAGAAGCTGGTAAAGG\       135bp
                       R:CCACAGAGACTCTCGGAAGC        

  ***VIM***            F:GAAATTGCAGGAGGAGATGC\       116bp
                       R:ATTCCACTTTGCGTTCAAGG        

  ***ZEB1***           F:TGCACTGAGTGTGGAAAAGC\       107bp
                       R:AAGCGTTTCTTGCAGTTTGG        
  --------------------------------------------------------------------

###### 

Primer sequences used in methylation-specific polymerase chain reaction

  Gene                          External Primer               T°C                         Primer sequence               T°C                           Size of product M   
  ----------------------------- ----------------------------- --------------------------- ----------------------------- ----------------------------- ------------------- -----
  ***ADAM23***                                                                            F:ATTGTTTTTTGGTTAGAATGTCG     F:ATTGTTTTTTTGTTAGAATGTTG     59                  100
  R:TAAAAAAAACACAAAAAACCGAACG   R:TAAAAAAAACACAAAAAACCAAACA                                                                                                               
  ***CDKN2A (p16)***            F:GGAGAGGGGGAGAGTAGGT         60                          F:CGGGGAGTAGTATGGAGTCGGCGGC   F:TGGGGAGTAGTATGGAGTTGGTGGT   64                  81
  R:CTACAAACCCTCTACCCACCT       R: GACCCCGAACCGCGACCGTAA      R: CAACCCCAAACCACAACCATAA                                                                                   

T= annealing temperature (°C), U= Unmethylated sequence, M= Methylated sequence.

###### 

Epidemiological, clinical and pathological characteristics of patients diagnosed with GCTB

  Sample   Age(y)   Sex   Anatomic location    Outcome     
  -------- -------- ----- -------------------- ----------- -----------
  1F       37       M     Proximal tibia L     ned         19 months
  2F       41       F     Distal radius R      ned         ned
  3F       24       M     Proximal femur L     ned         ned
  4F/P     52       F     Distal femur L       ned         ned
  5F       17       M     Scapula L            ned         ned
  6F       32       F     Olecranon R          11 months   ned
  7F/P     52       M     Distal femur L       11 months   ned
  8F/P     74       F     Distal femur L       19 months   ned
  9F       35       M     Distal femur L       ned         ned
  10F      33       M     Proximal tibia R     20 months   ned
  11F      21       F     Proximal tibia R     ned         ned
  12F      37       F     Proximal tibia L     ned         ned
  13F      13       F     \*                   ned         41 months
  14F/P    28       F     Distal femur R       19 months   ned
  15F      19       F     Sacrum               ned         ned
  16F      22       F     Distal fibula R      ned         ned
  17F      16       F     Ischium R            ned         ned
  18F      22       M     Distal fibula L      ned         20 months
  19F      27       M     Proximal humerus L   ned         No
  20F      69       F     Occipital            ned         ned
  21F      24       M     Proximal tibia R     22 months   ned
  22F      46       F     Distal radius L      ned         ned
  23F      58       F     Hemipelvis R         ned         ned
  24P      55       M     Proximal tíbia L     ned         ned
  25P      22       F     Ischium R            ned         65 months
  26P      57       M     Proximal tibia L     42 months   ned
  27P      34       M     Proximal tibia R     ned         ned
  28P      24       M     Distal radius L      ned         ned
  29P      27       M     Distal femur L       ned         ned
  30P      51       F     Scapula L            Yes\*       07 months
  31P      31       M     Wrist R              ned         ned
  32P      22       F     Distal radius R      ned         ned
  33P      41       M     Distal femur L       ned         01 months
  34P      24       F     Wrist L              ned         ned
  35P      41       M     Distal femur R       ned         ned
  36P      55       M     Distal radius L      ned         ned
  37P      41       F     Distal radius L      ned         ned
  38P      35       M     Thumb L              ned         ned
  39P      39       M     Proximal fibula L    ned         ned
  40P      53       M     Proximal tibia R     ned         ned
  41P      38       F     Distal femur L       ned         ned
  42P      19       F     Distal femur L       ned         ned

*Abbreviations: f: fresh tumor; p: paraffin-embedded tumor; f: female; m: male; r: right; l: left; ned: no evidence of disease,*\* = no information was obtained.

###### 

Methylation pattern of *ADAM23*and*CDKN2A (p16)* in 26 GCTB samples

  Samples   *ADAM23*   *p16*
  --------- ---------- -------
  3F        ˜          ˜
  4F        ˜          ˜
  7F        ˜          ˜
  9F        ˜          ˜
  10F       ˜          ˜
  11F       ˜          ˜
  12F       ˜          ˜
  13F       ˜          ˜
  14F       ˜          ˜
  15F       ˜          ˜
  18F       ˜          X
  19F       ˜          ˜
  23F       ˜          ˜
  24P       ˜          ˜
  25P       ˜          X
  28P       ˜          ˜
  29P       ™          ˜
  30P       ˜          ™
  35P       ˜          ™
  37P       ˜          ˜
  38P       ˜          ˜
  39P       ˜          ˜
  40P       ˜          ™
  41P       ˜          ˜
  42P       ™          ˜

legend: ˜: methylated genes; ™: unmethylated genes and x: not amplified.
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